MedTrace Logo

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

NCT00353496 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 264

Last updated 2025-03-05

Study results available
· View outcomes & findings →

Summary

The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.

Conditions

  • Endocrine Tumors

Interventions

DRUG

lanreotide (Autogel formulation)

120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.

DRUG

Placebo

Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.

Sponsors & Collaborators

Principal Investigators

  • Medical Director, Endocrinology · Ipsen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2013-04-30
Completion
2013-04-30
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Belgium
  • Czechia
  • Denmark
  • France
  • Germany
  • India
  • Italy
  • Netherlands
  • Poland
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00353496 on ClinicalTrials.gov